Nurix Therapeutics, Inc.: Form 10-Q for the period ended May 31, 2024
Filed with the SEC on Jul 11, 2024 and accepted by EDGAR at Jul 11, 2024, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-03-01 to 2024-05-31 | $12.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-12-01 to 2024-05-31 | $28.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2024-03-01 to 2024-05-31 | $48.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-12-01 to 2024-05-31 | $98.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-03-01 to 2024-05-31 | −$48.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-12-01 to 2024-05-31 | −$93.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-03-01 to 2024-05-31 | $90.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-12-01 to 2024-05-31 | $180.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-03-01 to 2024-05-31 | −$44.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-12-01 to 2024-05-31 | −$86.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-03-01 to 2024-05-31 | −$0.71 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-12-01 to 2024-05-31 | −$1.47 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-03-01 to 2024-05-31 | −$0.71 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-12-01 to 2024-05-31 | −$1.47 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-03-01 to 2024-05-31 | 62,377,551 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-12-01 to 2024-05-31 | 58,660,900 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-12-01 to 2024-05-31 | −$81.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-12-01 to 2024-05-31 | $4.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-05-31 | $116.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-05-31 | $450.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-05-31 | $511.0m | us-gaap:Assets |
| Current liabilities | At period end2024-05-31 | $80.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-05-31 | $140.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-05-31 | $370.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001549595-24-000098. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.